1Webb SD, Sherratt JA, Fish RG. Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology. Math Biosci 2002;179:113-129.
2Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M, Parmiani G, Fais S.Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-1316.
3Li JH, Rosen D, Sondel P, Berke G. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology 2002;105:267-277.
4Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol 2001;127:20-26.
5Michael-Robinson JM, Pandeya N, Cummings MC, Walsh MD, Young JP, Leggett BA, Purdie DM, Jass JR, Radford-SmithG L. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status. J Pathol 2003;201:46-54.
6rHouston A, Waldron-Lynch FD, Bennett MW, Roche D,O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. Int J Cancer 2003;107:209-214.
7Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 2001;85:1047-1054.
8Oka S, Tanaka S, Hiyama T, Kitadai Y, Yoshihara M,Shimamoto F, Haruma K, Chayama K. Human telomerase reverse transcriptase, p53 and Ki-67 expression and apoptosis in colorectal serrated adenoma. Scand J Gastroenterol 2002;37:1194-1200.
9Choi C, Benveniste EN. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev 2004;44:65-81.
10Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003;63:5573-5581.
